Physician profile
Scott E Capobianco
NPI 1275582066
$2,103.01
in general payments reported to CMS, 2019-2025
28 companies · $495 in 2025
The $495 reported for 2025 was more than what 80% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $501 · 2020: $128 · 2021: $51.54 · 2022: $411 · 2023: $330 · 2024: $186 · 2025: $495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $912 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $912.22 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $400.22 | 2019-2023 | Lo Loestrin Fe |
| Astellas Pharma US INC | $286.92 | 2019-2025 | Veozah |
| Biogen, INC. | $193.83 | 2024-2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $148.91 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $143.75 | 2025 | Spravato |
| Exeltis, USA INC. | $137.25 | 2019-2024 | Slynd |
| Mayne Pharma Commercial LLC | $106.21 | 2022-2025 | |
| Daiichi Sankyo INC. | $91.22 | 2019-2022 | |
| Hologic Sales and Service, LLC | $67.53 | 2019-2022 | |
| Aspira Women'S Health INC | $58.63 | 2021-2022 | |
| Organon LLC | $52.46 | 2022-2023 | |
| Pfizer INC. | $51.18 | 2024 | |
| Sumitomo Pharma America, INC. | $45.60 | 2023-2025 | Myfembree |
| Merck Sharp & Dohme LLC | $44.82 | 2019 | |
| Shield Therapeutics INC | $33.73 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mycovia Pharmaceuticals, INC. | $33.36 | 2022-2023 | Vivjoa |
| Pacira Pharmaceuticals Incorporated | $24.72 | 2022 | |
| Viiv Healthcare Company | $24.60 | 2022 | |
| Millicent US INC | $22.36 | 2025 | Intrarosa |
| Minerva Surgical, INC | $21.06 | 2023 | |
| Amag Pharmaceuticals, INC. | $17.74 | 2019 | |
| Allergan, INC. | $17.49 | 2019 | |
| Radius Health, INC. | $16.80 | 2020 | |
| Evofem Biosciences, INC. | $14.02 | 2022 | |
| Covidien LP | $12.90 | 2019 | |
| Ethicon US, LLC | $12.78 | 2019 | |
| Applied Medical Resources Corporation | $11.54 | 2021 | |
| Therapeuticsmd, INC. | $11.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Capobianco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.